ALGS - Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study

Aligos Therapeutics (ALGS) has dosed its first subject in Phase 1a/b trial (ALG-000184-201), evaluating ALG-000184 for the potential treatment of hepatitis B virus ((HBV)).ALG-000184 is a small molecule class II capsid assembly modulator ((CAM)) that works by targeting the HBV capsid assembly and the establishment covalently closed circular DNA (DNA structure that arises from the propagation of the virus).Initial topline data expected in 2H of 2021.The company is also developing ALG-010133, a S-antigen Transport-inhibiting Oligonucleotide Polymers molecule, which entered clinical development earlier this year; ALG-020572, an antisense oligonucleotide; and ALG125097, a small interfering RNA. Initially, Aligos plans to evaluate the antiviral activity of each of these drug candidates individually in Phase 1 umbrella trials before evaluating them in combination in subsequent trials.

For further details see:

Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study